TECH Price Prediction Next Week
Analysis and Insights
To predict the stock price of Bio-Techne (TECH) for the next trading week, we analyze both fundamental and technical factors.
Fundamental Analysis:
New Product Launch: Bio-Techne expanded its RNAscope probes portfolio, enhancing its position in spatial biology research. This could drive revenue growth and improve investor sentiment.
Citi's Price Target Adjustment: Citi lowered TECH's price target to $70 from $80, citing light investor appetite in the life science tools sector.
Federal Judge's Ruling: A preliminary injunction blocking NIH funding cuts is a positive catalyst for TECH, as it prevents potential funding reductions.
Technical Analysis:
- RSI: TECH's RSI is 42.89, indicating a neutral trend but nearing oversold territory.
- MACD: The MACD is slightly negative, suggesting bearish momentum.
- Fibonacci Levels: Support at $62.76 and resistance at $67.38.
Price Prediction:
Considering the positive product launch and blocked NIH cuts, TECH may see upward movement. However, Citi's lowered target and mixed technicals suggest caution. The stock is expected to trade around $67.50 next week.
Recommendation:
Buy TECH stock, targeting $67.50, as positive catalysts may outweigh technical challenges.
TECH Similar Chart Price Prediction
The price of TECH is predicted to go up 8.47%, based on the high correlation periods with IRWD. The similarity of these two price pattern on the periods is 98.56%.
TECH
IRWD
Up: 8.47%Similarity: 98.56%
TECH Revenue Forecast
TECH EPS Forecast
TECH FAQs
What is TECH revenue forecast for next quarter？
What is TECH eps forecast for next quarter？
TECH VS S&P500
While private payers currently do not cover the ExoDx biopsy test, getting reimbursement approvals along with expanded indications could allow for product revenue upward of $100 million, compared with under $50 million currently.
Bio-Techne is set to benefit from high market growth of biologics, which require protein inputs, and regulatory approvals of biosimilars could be an additional tailwind for protein growth.
Bio-Techne has meaningful exposure to academic health research, and funding for research including for pandemic preparedness could increase in a post-pandemic world.
TECH Analyst's Forecast
Patrick Donnelly
Citigroup
Hold
2025-03-04
Price Target
$80 → $70
Upside
+16.43%
Citi lowered the firm's price target on Bio-Techne to $70 from $80 and keeps a Neutral rating on the shares. The firm updated models in the life science tools and diagnostics group post the Q4 reports. Coming away from earnings, investor appetite for the sector "remains very light," primarily due to ongoing U.S. government pressure, the analyst tells investors in a research note. However, Citi sees pockets of the market to be constructive on, such as bioprocessing, where it believes a recovery is underway. Danaher (DHR) is the firm's top pick.
Catherine Schulte
Baird
Buy → Hold
2025-02-19
Price Target
$88 → $68
Upside
+3.34%
Catherine Schulte
Baird
Buy
2024-10-31
Price Target
$82 → $84
Upside
+13.9%
